180 related articles for article (PubMed ID: 9512763)
21. Neurologic protection by amifostine.
DiPaola RS; Schuchter L
Semin Oncol; 1999 Apr; 26(2 Suppl 7):82-8. PubMed ID: 10348265
[TBL] [Abstract][Full Text] [Related]
22. The effect of cytoprotective agents in platinum anticancer therapy.
Jakupec MA; Galanski M; Keppler BK
Met Ions Biol Syst; 2004; 42():179-208. PubMed ID: 15206103
[No Abstract] [Full Text] [Related]
23. [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
Vaira M; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Med; 2001 Aug; 92(4):207-11. PubMed ID: 11535965
[TBL] [Abstract][Full Text] [Related]
24. Recent developments and emerging options: the role of amifostine as a broad-spectrum cytoprotective agent.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):1-2. PubMed ID: 10348254
[No Abstract] [Full Text] [Related]
25. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
Kurbacher CM; Mallmann PK
Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
[TBL] [Abstract][Full Text] [Related]
26. Amifostine.
Viele C
Clin J Oncol Nurs; 1999 Jul; 3(3):128, 131. PubMed ID: 10690046
[No Abstract] [Full Text] [Related]
27. Long-term effects of platin and anthracycline derivatives and possible prevention strategies.
Hartmann JT
Front Radiat Ther Oncol; 2002; 37():92-100. PubMed ID: 11764674
[No Abstract] [Full Text] [Related]
28. [Nephropathy in Patients Undergoing Cancer Drug Therapy - Platinum Derivatives(Cisplatin and Carboplatin)].
Matsuoka A; Ando Y
Gan To Kagaku Ryoho; 2017 Mar; 44(3):200-203. PubMed ID: 28292990
[TBL] [Abstract][Full Text] [Related]
29. Amifostine in reducing cisplatin toxicity.
Markman M
Semin Oncol; 1998 Oct; 25(5):522-4. PubMed ID: 9783591
[TBL] [Abstract][Full Text] [Related]
30. Peripheral neuropathy: experimental findings, clinical approaches.
J Support Oncol; 2007 Feb; 5(2):61-3. PubMed ID: 17354318
[No Abstract] [Full Text] [Related]
31. [Development of cancer chemotherapy. Cytoprotective agents].
Lopez M
Clin Ter; 2001; 152(2):135-43. PubMed ID: 11441524
[No Abstract] [Full Text] [Related]
32. Understanding platinum-induced ototoxicity.
Langer T; am Zehnhoff-Dinnesen A; Radtke S; Meitert J; Zolk O
Trends Pharmacol Sci; 2013 Aug; 34(8):458-69. PubMed ID: 23769626
[TBL] [Abstract][Full Text] [Related]
33. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy.
Morgan KP; Buie LW; Savage SW
Ann Pharmacother; 2012 Feb; 46(2):276-81. PubMed ID: 22298599
[TBL] [Abstract][Full Text] [Related]
34. [Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention].
Montaguti M; Brandolini C; Ferri GG; Hatzopoulos S; Prete A; Pession A
Acta Otorhinolaryngol Ital; 2002 Feb; 22(1):14-8. PubMed ID: 12236007
[TBL] [Abstract][Full Text] [Related]
35. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity.
Asna N; Lewy H; Ashkenazi IE; Deutsch V; Peretz H; Inbar M; Ron IG
Life Sci; 2005 Mar; 76(16):1825-34. PubMed ID: 15698860
[TBL] [Abstract][Full Text] [Related]
36. [Anticancer chemotherapy. Prevention of toxicity].
Chvetzoff G; Bonnotte B; Chauffert B
Presse Med; 1998 Dec; 27(39):2106-12. PubMed ID: 9893704
[TBL] [Abstract][Full Text] [Related]
37. [Neuropathy induced by antineoplastic drugs].
Kusunoki J; Saito T
Brain Nerve; 2008 Feb; 60(2):131-6. PubMed ID: 18306660
[TBL] [Abstract][Full Text] [Related]
38. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity.
Dana R; Kachhwaha VS
Indian J Cancer; 1996 Dec; 33(4):168-70. PubMed ID: 9254992
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin nephropathy: is cytotoxicity avoidable?
Razzaque MS
Nephrol Dial Transplant; 2007 Aug; 22(8):2112-6. PubMed ID: 17617652
[No Abstract] [Full Text] [Related]
40. How to keep kidneys safe while shrinking tumors: the conundrum of cisplatin action.
Goligorsky MS
Am J Physiol Renal Physiol; 2007 Jul; 293(1):F50-1. PubMed ID: 17507601
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
